Switch Language

Brand Navigation Banner DE

76 years, Metastatic NSCLC adenocarcinoma

33 years, Papillary thyroid cancer

85 years, MSI-high colorectal cancer

PATIENT CASE

76 years, Metastatic NSCLC adenocarcinoma

Alt tag

Overview

Clinical presentation1

• Multiple bilateral pulmonary nodules

• Metastases in liver, bone and brain

• Negative for known drivers (including KRAS, EGFR, BRAF, MET, ERBB2, ALK, ROS1, RET)

 

Prior treatment1,2,

• No prior systemic therapy, surgery or radiotherapy

• Patient refused platinum doublet therapy

 

EPS15–NTRK1 gene fusion detected by NGS1

 

Treatment

Treatment with Larotrectinib 100 mg twice daily2

• Confirmed partial response at 8 weeks
   (34% reduction)

• Near complete response of all brain
   metastases (95% reduction)

 

Current status2

Larotrectinib treatment ongoing 
   for >18 months (Feb 2020)

 

Baseline

Alt tag
Alt tag
Alt tag

8 weeks

Alt tag
Alt tag
Alt tag

16 weeks

Alt tag
Alt tag
Alt tag

Larotrectinib is effective in TRK fusion lung cancer

Efficacy in TRK fusion lung cancer2

• N=14 patients 
  (N=7 with baseline CNS metastases)

71% ORR all (95% CI 42-92)
  57% ORR CNS (95% CI 18-90)

91% 1-year OS rate (95% CI 74-100)

 

Safety in TRK fusion lung cancer2

• AEs primarily grade 1 and 2

• Treatment-related grade 3 AEs 
  in 2 patients (14%), no grade 4 TRAE

• No permanent discontinuations 
  due to TRAE

 

Maximum change in tumor size (%)2

Alt tag

Based on data cut-off July, 2019; presented at ESMO Virtual Congress 2020. AE, adverse event; CNS, central nervous system; ORR, objective response rate; OS, overall survival; TRAE, treatment-related adverse event

Fachinformation Vitrakvi®

Picture of the actual patient has been redacted. 

References:

  • Rosen EY, et al. Larotrectinib demonstrates CNS efficacy in TRK fusion-positive solid tumors. JCO Precis Oncol 2019; published online May 16, 2019. doi: 10.1200/PO.19.00009. Return to content
  • Drilon A, et al. Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion lung cancer. Ann Oncol 2020;31(suppl 4):S834, Abstract 1289P. Poster presentation at ESMO Virtual Congress, September 19–21, 2020. Return to content